Literature DB >> 32122246

[Stakeholders' experiences with flexible and integrative treatment models in German child and adolescent psychiatry according to § 64b SGB V - A qualitative study].

Julian Schwarz1, Annette Duve2, Sabine Hoffmann2, Philip Heiser3, Martin Heinze1, Sebastian von Peter1.   

Abstract

Stakeholders' experiences with flexible and integrative treatment models in German child and adolescent psychiatry according to § 64b SGB V - A qualitative study Abstract. Background and Aims: Since 2013, new possibilities for flexible and integrative forms of treatment (FIT) exist within the German mental healthcare system. These FIT models, created according to § 64b of the Social Security Code V, have been implemented in adult as well as child and adolescent psychiatry over the past years. This paper investigates stakeholders' experiences with these innovative FIT models.
Methods: Focus groups were conducted in two hospital departments that had implemented a FIT model according to § 64b. In total, 36 participants were included, comprising employees, patients, and their caretakers. We also conducted a thematic analysis.
Results: According to all stakeholders, these forms of acute outpatient treatment form a core component of FIT models that may serve to prepare, replace, or follow-up on inpatient treatment. In addition, the flexibility of treatment and increased continuity of care were mentioned as benefits of FIT models according to § 64b. Third, these FIT models allow for a better integration of caretakers in the treatment of their kin, which also produces various challenges for this stakeholder group. Conclusions: The introduction of FIT models in German child and adolescent psychiatry has complex implications for the treatment process and the experiences of all stakeholders. They perceive it as a needs-adapted extension of current forms of psychiatric support.

Entities:  

Keywords:  Behandlungskontinuität; Modellvorhaben; Versorgungsforschung; continuity of care; flexible and integrative care; health service research; qualitative Gesundheitsforschung; qualitative health research; settingübergreifend; treatment models

Year:  2020        PMID: 32122246     DOI: 10.1024/1422-4917/a000716

Source DB:  PubMed          Journal:  Z Kinder Jugendpsychiatr Psychother        ISSN: 1422-4917


  4 in total

1.  Changes in German Mental Health Care by Implementing a Global Treatment Budget-A Mixed-Method Process Evaluation Study.

Authors:  Julian Schwarz; Laura Galbusera; Andreas Bechdolf; Thomas Birker; Arno Deister; Annette Duve; Philip Heiser; Kerit Hojes; Sonja Indefrey; Jakob Johne; Burkhard Rehr; Sandeep Rout; Harald Scherk; Anna Schulz-Du Bois; Bettina Wilms; Dyrk Zedlick; Manfred Zeipert; Martin Heinze; Sebastian von Peter
Journal:  Front Psychiatry       Date:  2020-05-25       Impact factor: 4.157

2.  [Flexible and integrative treatment in psychiatry: implementation of specific care components at model and standard care clinics in Germany (PsychCare study)].

Authors:  Julian Schwarz; Yuriy Ignatyev; Fabian Baum; Anne Neumann; Bettina Soltmann; Andrea Pfennig; Jürgen Timm; Martin Heinze; Sebastian von Peter
Journal:  Nervenarzt       Date:  2021-12-07       Impact factor: 1.297

3.  Lengths of inpatient stay and sick leave of patients with mental diseases: disorder-specific effects of flexible and integrated treatment programs in Germany.

Authors:  Fabian Baum; Jochen Schmitt; Martin Seifert; Roman Kliemt; Denise Kubat; Stefanie March; Dennis Häckl; Andrea Pfennig; Enno Swart; Anne Neumann
Journal:  Transl Psychiatry       Date:  2022-09-07       Impact factor: 7.989

4.  Flexible and Integrative Psychiatric Care Based on a Global Treatment Budget: Comparing the Implementation in Germany and Poland.

Authors:  Julian Schwarz; Andrzej Cechnicki; Jan Godyń; Laura Galbusera; Daria Biechowska; Beata Galińska-Skok; Izabela Ciunczyk; Yuriy Ignatyev; Felix Muehlensiepen; Bettina Soltmann; Jürgen Timm; Sebastian von Peter; Marek Balicki; Jacek Wciórka; Martin Heinze
Journal:  Front Psychiatry       Date:  2022-01-07       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.